Charles River Laboratories International, Inc. has sustained modest revenue growth driven by its diversified service segments including Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. Despite a sharp decline in net income largely attributable to margin compression and regulatory headwinds, the company maintains strong operating cash flows supporting capital investments and share repurchases. Regulatory shifts toward reducing traditional animal testing models pose considerable risks, prompting Charles River to enhance its portfolio through acquisitions and technology adaptation. Leadership transitions and governance fortifications are aligned with navigating these market complexities. Monitoring NAM adoption rates, biosimilar market evolution, and margin recovery initiatives will be critical for assessing future trajectory.